Omalizumab as a new therapeutic approach for children with severe asthma

Postepy Dermatologii i Alergologii

Volumn 31, Issue 1, 2014, Pages 45-46

  Jerzyńska, Joanna ^a   Sztafińska, Anna ^a   Woicka Kolejwa, Katarzyna ^a   Stelmach, Iwona ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Immunotherapy; Omalizumab; Severe asthma

Indexed keywords

CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; IMMUNOGLOBULIN E ANTIBODY; MONTELUKAST; OMALIZUMAB; SALBUTAMOL;

ADOLESCENT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; BRONCHODILATATION; CASE REPORT; CHILDHOOD; CORTICOSTEROID THERAPY; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; LUNG FUNCTION; MALE; MEDICAL HISTORY; OSTEOPENIA; QUALITY OF LIFE; SKIN TEST; SUBCUTANEOUS SPECIFIC IMMUNOTHERAPY; TREATMENT FAILURE; UPPER RESPIRATORY TRACT INFECTION;

EID: 84896777656     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: 10.5114/pdia.2014.40660     Document Type: Article

References (8)

1. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364: 1005-15.
2. Steiss JO, Schmidt A, Nährlich L, et al. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents. Allergy Asthma Proc 2012; 33: 77-81.
3. Thomson NC, Chaudhuri R. Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med 2012; 6: 27-40.
4. Lafeuille MH, Dean J, Zhang J, et al. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. Ann Allergy Asthma Immunol 2012; 109: 59-64.
5. Jilcy M, Wilbert SA, Dipak C. Therapeutic options for severe asthma. Arch Med Sci 2012; 8: 589-97.
6. Brzyski P, Cichocka-Jarosz E, Tobiasz-Adamczyk B, et al. Theoretical validity and reliability of Vespide Quality of Life Questionnaire in Polish adolescents with Hymenoptera venom allergy. Postep Derm Alergol 2012; 29: 8-13.
7. Niedoszytko M, Majkowicz M, Chełmińska M, et al. Quality of life, anxiety, depression and satisfaction with life in patients treated with insect venom immunotherapy. Postep Derm Alergol 2012; 29: 74-9.
8. Hayden ML. Immunoglobulin E-mediated airway inflammation is active in most patients with asthma. J Am Acad Nurse Pract 2007; 19: 439-49.